Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Source:
    PR Newswire (USA), January 2, 2008, 3pp
  • Additional Information
    • Abstract:
      PRNewswire-FirstCall -- Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has assigned priority review status to the company's New Drug Application (NDA) for sugammadex. Sugammadex is specifically designed to reverse the effects of certain muscle relaxants, marketed in the United States as ZEMURON(R) (rocuronium bromide) and vecuronium bromide...